Creative Planning decreased its position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 3.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 14,376 shares of the company’s stock after selling 559 shares during the period. Creative Planning’s holdings in Crispr Therapeutics were worth $589,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Xact Kapitalforvaltning AB purchased a new stake in Crispr Therapeutics during the 2nd quarter valued at $207,000. Commonwealth Equity Services LLC boosted its position in Crispr Therapeutics by 5.9% in the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after purchasing an additional 986 shares during the last quarter. Buckley Wealth Management LLC bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $236,000. Carnegie Capital Asset Management LLC purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $1,064,000. Finally, Moody Aldrich Partners LLC bought a new position in shares of Crispr Therapeutics in the 2nd quarter worth approximately $1,838,000. 49.81% of the stock is owned by hedge funds and other institutional investors.
CRSP has been the topic of several recent research reports. Oppenheimer increased their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, November 25th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday. Piper Jaffray Companies reissued a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Finally, Roth Capital increased their target price on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $69.54.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at approximately $390,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
Shares of CRSP traded up $1.66 during midday trading on Friday, hitting $72.37. The stock had a trading volume of 893,783 shares, compared to its average volume of 703,877. Crispr Therapeutics AG has a 1 year low of $22.22 and a 1 year high of $74.00. The stock’s 50 day moving average is $54.81 and its 200 day moving average is $47.38. The firm has a market cap of $3.95 billion, a PE ratio of -21.04 and a beta of 3.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, equities research analysts expect that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: How is the Producer Price Index calculated?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.